PHARMACY

NACDS data finds retail stores with pharmacies have annual impact of 17 percent of GDP

BY Alaric DeArment

ALEXANDRIA, Va. Though their sales alone total $827 billion, retail stores that operate pharmacies have a total economic effect of $2.42 trillion every year, according to economic analysis that the National Association of Chain Drug Stores released Thursday.

The analysis, part of NACDS’ 2008 Chain Pharmacy Industry Profile, shows that every $1 spent in these stores creates a ripple effect of $2.93 throughout other segments of the economy, including manufacturing, information technology, construction, real estate, transportation and others.

Stores that operate pharmacies—including chain and independent drug stores, supermarkets and mass merchandisers—have annual sales of $827 billion.

The 39,000 chain pharmacies across the country dispensed more than 2.5 billion prescriptions last year, or about 72 percent of the total filled, NACDS said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Glue-like bacterial sugar could lead to vaccine

BY Alaric DeArment

LONDON A study has found that when manipulated with chemicals, a sugar that drug-resistant bacteria secrete triggered an immune response in animals.

The study, presented last week at the Dublin, Ireland, meeting of the Society for General Microbiology used a glue-like sugar that bacteria produce to protect themselves from antibiotics called PNAG.

PNAG alone does not produce an immune response in most people and animals, but the researchers, from the Harvard Medical School, hope that formulations of it do.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA announces likely delay on Novo Nordisk diabetes drug

BY Alaric DeArment

WASHINGTON The Food and Drug Administration has announced that it will be unable to meet the user fee deadline for a timely approval of Novo Nordisk’s drug liragludite.

The FDA will not be able to make an approvability decision until March 23 for the drug, a treatment for Type 2 diabetes. Novo Nordisk had submitted an approval application for the drug on May 23.

The standard review period for FDA action on approval applications is 10 months. Because the agency’s advisory committee meeting will take place shortly before March 23, however, its decision will probably be delayed by a further two months, the company said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?